Insulet Co. (NASDAQ:PODD) Receives $290.67 Consensus PT from Brokerages

Insulet Co. (NASDAQ:PODDGet Rating) has been assigned a consensus recommendation of “Moderate Buy” from the fifteen brokerages that are covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell rating, two have issued a hold rating and eight have assigned a buy rating to the company. The average 12-month price objective among analysts that have covered the stock in the last year is $290.67.

Several research firms recently weighed in on PODD. Morgan Stanley increased their price target on shares of Insulet from $244.00 to $273.00 and gave the company an “equal weight” rating in a research report on Monday, August 8th. Canaccord Genuity Group raised their price objective on shares of Insulet from $250.00 to $290.00 and gave the stock a “buy” rating in a report on Friday, August 5th. Robert W. Baird raised their price objective on shares of Insulet from $245.00 to $300.00 and gave the stock an “outperform” rating in a report on Friday, August 5th. Piper Sandler raised their price objective on shares of Insulet from $230.00 to $235.00 and gave the stock a “neutral” rating in a report on Friday, August 5th. Finally, BTIG Research raised their price objective on shares of Insulet to $285.00 in a report on Tuesday, August 9th.

Insulet Stock Performance

NASDAQ:PODD opened at $241.25 on Friday. The company has a market capitalization of $16.74 billion, a PE ratio of 482.50 and a beta of 0.73. The company has a 50 day simple moving average of $256.45 and a two-hundred day simple moving average of $240.24. The company has a debt-to-equity ratio of 3.28, a quick ratio of 3.54 and a current ratio of 4.69. Insulet has a fifty-two week low of $181.00 and a fifty-two week high of $324.81.

Insulet (NASDAQ:PODDGet Rating) last released its earnings results on Thursday, August 4th. The medical instruments supplier reported ($0.06) earnings per share for the quarter, missing analysts’ consensus estimates of $0.21 by ($0.27). The firm had revenue of $299.40 million for the quarter, compared to analyst estimates of $290.87 million. Insulet had a net margin of 2.94% and a return on equity of 13.83%. The business’s revenue for the quarter was up 13.8% compared to the same quarter last year. During the same period in the prior year, the company posted $0.10 EPS. Research analysts anticipate that Insulet will post 0.76 earnings per share for the current year.

Insider Transactions at Insulet

In related news, EVP Bret Christensen sold 2,900 shares of the business’s stock in a transaction that occurred on Wednesday, August 24th. The shares were sold at an average price of $264.24, for a total transaction of $766,296.00. Following the completion of the transaction, the executive vice president now owns 19,551 shares of the company’s stock, valued at $5,166,156.24. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. In related news, Director Shacey Petrovic sold 15,000 shares of the business’s stock in a transaction that occurred on Friday, July 1st. The shares were sold at an average price of $222.90, for a total transaction of $3,343,500.00. Following the completion of the transaction, the director now owns 13,695 shares of the company’s stock, valued at $3,052,615.50. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, EVP Bret Christensen sold 2,900 shares of the business’s stock in a transaction that occurred on Wednesday, August 24th. The shares were sold at an average price of $264.24, for a total transaction of $766,296.00. Following the transaction, the executive vice president now directly owns 19,551 shares of the company’s stock, valued at approximately $5,166,156.24. The disclosure for this sale can be found here. Corporate insiders own 0.90% of the company’s stock.

Institutional Investors Weigh In On Insulet

Hedge funds have recently bought and sold shares of the stock. Blueshift Asset Management LLC lifted its position in Insulet by 80.2% during the first quarter. Blueshift Asset Management LLC now owns 2,964 shares of the medical instruments supplier’s stock valued at $790,000 after purchasing an additional 1,319 shares during the last quarter. AIA Group Ltd lifted its holdings in shares of Insulet by 190.3% in the 1st quarter. AIA Group Ltd now owns 3,678 shares of the medical instruments supplier’s stock worth $980,000 after acquiring an additional 2,411 shares during the last quarter. TD Asset Management Inc. lifted its holdings in shares of Insulet by 18.6% in the 1st quarter. TD Asset Management Inc. now owns 44,991 shares of the medical instruments supplier’s stock worth $11,985,000 after acquiring an additional 7,040 shares during the last quarter. Swiss National Bank lifted its holdings in shares of Insulet by 14.1% in the 1st quarter. Swiss National Bank now owns 298,677 shares of the medical instruments supplier’s stock worth $79,565,000 after acquiring an additional 36,800 shares during the last quarter. Finally, First Foundation Advisors lifted its holdings in shares of Insulet by 27.9% in the 1st quarter. First Foundation Advisors now owns 1,187 shares of the medical instruments supplier’s stock worth $316,000 after acquiring an additional 259 shares during the last quarter.

Insulet Company Profile

(Get Rating)

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. It offers Omnipod System, a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, as well as its wireless companion, the handheld personal diabetes manager.

Recommended Stories

Analyst Recommendations for Insulet (NASDAQ:PODD)

Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.